期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期非小细胞肺癌一线治疗后的维持治疗

Maintenance therapy after first-line therapy in advanced non-small cell lung cancer
原文传递
导出
摘要 维持治疗是目前晚期非小细胞肺癌研究的热点之一,包括继续维持治疗和换药维持治疗。维持治疗可能对延长患者总生存期有益。本文综述晚期非小细胞肺癌一线治疗后维持治疗的研究进展。 Maintenance therapy （include continuation maintenance and switch maintenance）for patients with advanced non-small cell lung cancer may increase overall survival rate. This review focuses on the progress of maintenance therapy for patients with advanced non-small cell lung cancer.
作者 李勇 李子明 陆舜
机构地区 上海市肺部肿瘤临床医学中心
出处 《世界临床药物》 CAS 2012年第4期206-210,共5页 World Clinical Drug
关键词 抗肿瘤药物 非小细胞肺癌 药物疗法 anti-mmar drugs non-small cell lung cancer drug therapy
分类号 R979.1 [医药卫生—药品] R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Socinski MA,Schell MJ,Peterman A. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage Ⅲ B/Ⅳ non-small-cell lung cancer[J].Journal of Clinical Oncology,2002,(05):1335-1343.doi:10.1200/JCO.20.5.1335.
  • 2Park JO,Kim SW,Ahn JS. Phase Ⅲ trial of two versus four additiona cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer[J].Journal of Clinical Oncology,2007,(33):5233-5239.doi:10.1200/JCO.2007.10.8134.
  • 3Smith IE,O'Brien ME,Talbot DC. Duration of chemotherapy in advanced non-small-cell lung cancer:a randomized trial of three versus six courses of mitomycin,vinblastine,and cisplatin[J].Journal of Clinical Oncology,2001,(05):1336-1343.
  • 4von P essen C,Bergman B,Andresen O. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer[J].British Journal of Cancer,2006,(08):966-973.
  • 5Barata F,Parente B,Teixeira E. Optimal duration of chemotherapy in non-small-cell lung cancer:multicenter,randomized,prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gerncitabine[J].JOURNAL OF THORACIC ONCOLOGY,2007,(08):S666.doi:10.1097/01.JTO.0000283943.70775.a5.
  • 6Belani CP,Barstis J,Perry MC. Multi-center,randomized tria for stage Ⅲ B or Ⅳ non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation[J].Journal of Clinical Oncology,2003,(15):2933-2939.doi:10.1200/JCO.2003.02.563.
  • 7Brodowicz T,Krzakowski M,Zwitter M. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:A phase Ⅲ trial[J].Lung Cancer,2006,(02):155-163.doi:10.1016/j.lungcan.2006.01.006.
  • 8Belani CP,Waterhouse DM,Ghazal H. Phase Ⅲ study of maintenance gemcitabine (G) and best supportive care (BSC)versus BSC,following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)[J].Journal of Clinical Oncology,2010,(Suppl 7506):S540.
  • 9Perol M,Chouaid C,Milleron BJ. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC:IFCT-GFPC 0502 phase Ⅲ study[J].Journal of Clinical Oncology,2010,(Suppl 7507):S540.
  • 10Paz-Ares LG,De Marinis F,Dediu M. PARAMOUNT:Phase Ⅲ study of maintenance pemetrexed (pern) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)[A].2011.
世界临床药物
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部